Live Blog

MARKET WRAP: Sensex gains 184 pts, ends at fresh closing high of 40,653.74

All that happened in markets today.

SI Reporter New Delhi
Brokers trade at their computer terminals at a stock brokerage firm in Mumbai (

3 min read Last Updated : Nov 07 2019 | 4:37 PM IST

3:53 PM

Realty stocks log gains on stimulus measure

3:52 PM

Nifty snapshot

3:51 PM

Sensex heat map

3:51 PM

Market at close

3:36 PM

CLOSING BELL

The S&P BSE Sensex rallied 184 points or 0.45 per cent to end at 40,653.74 and NSE's Nifty50 ended above 12,000-mark at 12,016.10, up 50 points or 0.42 per cent. 

3:13 PM

RESULTS IMPACT | UPL slips over 3% post Q2 results announcement

2:59 PM

RESULTS IMPACT | Sun Pharma climbs nearly 3% post Q2 nos

2:59 PM

Kotak Institutional Equities on realty sector

Effective execution remains crucial. As highlighted previously, listed real estate stocks have had fewer concerns on leverage, and accordingly the special window is less likely to impact them. It is challenging to estimate the extent of stressed debt which will benefit from this scheme. The fund aggregates to 6% of the real estate loan book in India.

2:57 PM

COMMENT :: JLL India on AIF for realty sector

The registration of projects with RERA being one of the necessary conditions, this measure will have a far reaching impact on states which are lagging behind in the implementation of the reform. At the same time, states which have not implemented RERA may not benefit from this liquidity shot.

JLL’s recent study showed that Delhi NCR contributed to more than 60% of delayed residential units followed by Mumbai, constituting nearly one-fifth of the overall delayed units across the top seven cities in India. It has come at an opportune moment when the residential market is tackling the headwinds from the trickle down impact of the series of reforms and economic slowdown. While it will boost consumer sentiment and enhance confidence, it will act as a strong catalyst in pushing the sales velocity

(Source: Ramesh Nair, CEO & Country Head, JLL India)

2:57 PM

EARNINGS ALERT | Sun Pharma

  • Consolidated net profit at Rs 1,064.09 cr against loss of Rs 269.60 cr in Q2FY19;
  • Total revenue at 8,123.35 cr, up 17% YoY; 
  • EPS at Rs 4.43 against Rs (-) 1.12 in Q2FY19;
  • Ebidta margin at 22%

2:56 PM

NEWS ALERT | Syndicate Bank reports FY19 provision divergence at Rs 1,184 cr: BSE filing

2:54 PM

Edelweiss on Infosys

We attended Infosys’ analyst meet and came away convinced that the company is set firmly on road to deliver excellent shareholder value as: 1) concerns regarding the recent whistleblower allegations were addressed succinctly by Mr. Nandan Nilekani, non-executive chairman of the board. While investigation is underway, the chairman’s unwavering faith in the internal finance team and in the sanctity of numbers instills immense confidence; and 2) the company’s strategic investments in sales force, talent and localisation are largely behind and Infosys is in pole position to benefit from large deal momentum while cost optimisation levers are expected to drive earnings growth. We concur with the company’s thesis on the inevitability of digital and believe Infosys has the right tools to cash in on the opportunity. Maintain ‘BUY’ with TP of INR955 (20x Q4FY21E EPS). 
 
 

2:52 PM

COMMENT :: IIFL on realty sector

We believe that the stuck projects with purely last-mile funding issue (no litigations, positive net worth) will be benefitted. So overall, while this is a positive move and a well-intended first step to resolve the crisis in the real estate sector, we also see significant challenges in its implementation, considering the complexity of the challenge and multiplicity of stakeholder involvement in projects. From a listed developers perspective, none of the related projects are stuck for want of liquidity and, hence, there would be no direct impact on such developers

(Source: Mohit Agrawal, analyst, IIFL Institutional Equities)

2:51 PM

NEWS ALERT | Both banks and mkts are differentiating between good and bad NBFCs: RBI Guv

2:46 PM

BROKERAGE RADAR | Edelweiss Securities on Lupin

Current valuation of 17.0x FY21E EPS offers an attractive entry point, in our view. A promising respiratory and biosimilar franchise may unlock value in the long run. We maintain ‘BUY/SP’ with TP of Rs 900 (22x December 2020E earnings).

Topics :MarketsMARKET WRAP

First Published: Nov 07 2019 | 7:19 AM IST